14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DRIO vs XBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). DRIO carries a Unified Composite Score of 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin), whereas XBIO carries 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin).
Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRIO vs XBIO. Trailing 12-month operating profitability (DRIO -142.7% vs XBIO -81.0%) and valuation multiples (DRIO 10.6x vs XBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6M market capitalization and -81.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DRIO vs XBIO Key Questions & Quantitative Answers
As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). DRIO carries a Unified Composite Score of 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin), whereas XBIO carries 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin). Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DRIO leads the Growth & Scale pillar: DRIO posts +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin), compared with XBIO at +12.0% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (100.0% gross margin, -81.0% operating margin). On trailing 12-month operating scale, DRIO generates $21M in USD-normalized revenue versus $3.3M for XBIO. In operating R&D and SG&A reinvestment, DRIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XBIO.
DRIO screens cheaper on headline valuation multiples. DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin), whereas XBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-55.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRIO (-46.6% ROE) versus XBIO (-47.0% ROE) capital efficiency.
In options market volatility and institutional positioning, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk). By comparison, XBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 99% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.